Table 1.
Baseline demographic and disease characteristics
| <50 years | ≥50 and <65 years | ≥65 years | ||||
| Placebo (n=254) |
Baricitinib 4 mg (n=259) | Placebo (n=349) |
Baricitinib 4 mg (n=319) | Placebo (n=113) | Baricitinib 4 mg (n=136) | |
| Age | 39.7 (7.5) | 40.0 (7.2) | 56.9 (4.3) | 56.5 (4.0) | 69.5 (4.1) | 69.6 (4.2) |
| Female, n (%) | 218 (85.8) | 214 (82.6) | 263 (75.4) | 246 (77.1) | 90 (79.6) | 102 (75.0) |
| Region | ||||||
| Asia including Japan, n (%) | 72 (28.3) | 67 (25.9) | 85 (24.4) | 88 (27.6) | 24 (21.2) | 25 (18.4) |
| Central and South America, Mexico, n (%) | 72 (28.3) | 72 (27.8) | 76 (21.8) | 72 (22.6) | 21 (18.6) | 28 (20.6) |
| Eastern Europe, n (%) | 42 (16.5) | 37 (14.3) | 58 (16.6) | 58 (18.2) | 23 (20.4) | 25 (18.4) |
| Western Europe, n (%) | 12 (4.7) | 13 (5.0) | 27 (7.7) | 24 (7.5) | 15 (13.3) | 16 (11.8) |
| USA and Canada, n (%) | 27 (10.6) | 34 (13.1) | 59 (16.9) | 44 (13.8) | 21 (18.6) | 30 (22.1) |
| Rest of world, n (%) | 29 (11.4) | 36 (13.9) | 44 (12.6) | 33 (10.3) | 9 (8.0) | 12 (8.8) |
| Duration of RA*, years | 5.9 (5.7) | 6.2 (6.1) | 8.4 (8.1) | 8.6 (8.9) | 11.2 (9.6) | 9.8 (10.0) |
| <1 year, n (%) | 46 (18.1) | 41 (15.9) | 49 (14.0) | 50 (15.7) | 10 (8.9) | 22 (16.2) |
| ≥1 to <5 years, n (%) | 94 (37.0) | 101 (37.1) | 111 (31.8) | 102 (32.0) | 29 (25.9) | 30 (22.1) |
| ≥5 to <10 years, n (%) | 62 (24.4) | 63 (24.4) | 79 (22.6) | 67 (21.0) | 25 (22.3) | 36 (26.5) |
| ≥10 years, n (%) | 52 (20.5) | 53 (20.5) | 110 (31.5) | 100 (31.3) | 48 (42.9) | 48 (35.3) |
| ACPA positive, n (%) | 214 (84.3) | 208 (80.3) | 288 (82.5) | 269 (84.3) | 94 (83.2) | 113 (83.1) |
| RF positive, n (%) | 223 (87.8) | 223 (86.1) | 304 (87.1) | 272 (85.3) | 95 (84.1) | 117 (86.0) |
| Swollen joint count of 66 | 14.0 (8.5) | 14.6 (8.2) | 15.1 (9.6) | 14.6 (7.8) | 15.1 (7.4) | 14.2 (7.4) |
| Tender joint count of 68 | 22.8 (12.6) | 23.9 (13.3) | 23.9 (14.7) | 23.8 (13.4) | 24.7 (14.7) | 22.9 (13.1) |
| hsCRP, mg/L | 18.1 (18.7) | 19.6 (20.9) | 20.0 (20.7) | 20.3 (20.8) | 18.1 (25.2) | 18.2 (21.2) |
| DAS28-hsCRP | 5.6 (0.9) | 5.7 (0.9) | 5.7 (1.0) | 5.7 (0.9) | 5.6 (0.9) | 5.7 (0.9) |
| DAS28-ESR | 6.3 (1.0) | 6.3 (0.9) | 6.3 (1.0) | 6.4 (0.9) | 6.4 (1.0) | 6.4 (0.9) |
| CDAI | 36.6 (11.7) | 37.3 (12.0) | 37.0 (13.2) | 37.5 (11.8) | 37.3 (12.2) | 37.9 (11.8) |
| SDAI | 38.4 (12.1) | 39.3 (12.6) | 39.0 (13.6) | 39.5 (12.4) | 39.1 (12.8) | 39.7 (12.4) |
| HAQ-DI | 1.5 (0.6) | 1.5 (0.6) | 1.6 (0.7) | 1.6 (0.7) | 1.6 (0.6) | 1.6 (0.7) |
Data are mean (SD) unless otherwise noted.
*Time since diagnosis.
ACPA, anti-citrullinated peptide antibody; CDAI, Clinical Disease Activity Index; DAS28, Disease Activity Score based on 28 joints; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; hsCRP, high-sensitivity C-reactive protein; RA, rheumatoid arthritis; RF, rheumatoid factor; SDAI, Simple Disease Activity Index.